Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

13.7K
The goal of this protocol is to demonstrate the intra-prostatic injection of prostate cancer cells, with subsequent castration. Orthotopic pre-clinical models of androgen-dependent and castration-resistant prostate cancer are critical to study the disease in the context of a clinically relevant tumor microenvironment and an immunocompetent host.
13.7K
Murine Prostate Micro-dissection and Surgical Castration08:49

Murine Prostate Micro-dissection and Surgical Castration

47.5K
This manuscript describes the protocols for prostate micro-dissection and surgical castration in the laboratory mouse. We also depict representative results produced by these protocols. Finally, we discuss the advantages and utilization of these...
47.5K
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

7.2K
Therapy resistance often develops in patients with advanced prostate cancer, and in some cases, cancer progresses to a lethal subtype called neuroendocrine prostate cancer. Assessing the small non-coding RNA-mediated molecular changes that facilitate this transition would allow better disease stratification and identification of causal mechanisms that lead to development of neuroendocrine prostate...
7.2K
Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

14.0K
Resistance to cancer therapies contributes to disease progression and death. Determining the mechanistic underpinnings of resistance is crucial for improving therapeutic response. This manuscript details the protocol to generate taxane-resistant cell models of prostate cancer (PC) to help dissecting the pathways involved in progression to Docetaxel resistance in PC...
14.0K
Establishment and Analysis of Three-Dimensional (3D) Organoids Derived from Patient Prostate Cancer Bone Metastasis Specimens and their Xenografts07:21

Establishment and Analysis of Three-Dimensional (3D) Organoids Derived from Patient Prostate Cancer Bone Metastasis Specimens and their Xenografts

9.8K
Three-dimensional cultures of patient BMPC specimens and xenografts of bone metastatic prostate cancer maintain the functional heterogeneity of their original tumors resulting in cysts, spheroids and complex, tumor-like organoids. This manuscript provides an optimization strategy and protocol for 3D culture of heterogeneous patient derived samples and their analysis using...
9.8K
Generation of Tumor Organoids from Genetically Engineered Mouse Models of Prostate Cancer08:54

Generation of Tumor Organoids from Genetically Engineered Mouse Models of Prostate Cancer

11.3K
We show a method for necropsy and dissection of mouse prostate cancer models, focusing on prostate tumor dissection. A step-by-step protocol for generation of mouse prostate tumor organoids is also...
11.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effects of beta-cypermethrin on the antioxidant system and gut microbiota in Eisenia fetida.

Environmental toxicology and pharmacology·2026
Same author

Savolitinib in MET-amplified gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial.

Nature medicine·2026
Same author

Graphene oxide-modified Ni<sub>1.5</sub>Mg<sub>1.5</sub>Al<sub>1</sub>-LDH/g-C<sub>3</sub>N<sub>4</sub> composites for efficient photocatalytic degradation toward ciprofloxacin.

Environmental research·2026
Same author

Mutual interactions between HG-LG gellan gum and tea polyphenols: Concentration-dependent structural modulation and enhanced antioxidant stability.

Food chemistry: X·2026
Same author

Correction: Construction and validation of a predictive model for exclusive breastfeeding at discharge based on the information-motivation-behavioral skills theory.

Frontiers in medicine·2025
Same author

Construction and validation of a predictive model for exclusive breastfeeding at discharge based on the information-motivation-behavioral skills theory.

Frontiers in medicine·2025

Related Experiment Video

Updated: Jan 20, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.7K

PARP Inhibitor Olaparib and Its Combination Therapy in Metastatic Castration-resistant Prostate Cancer: A Systematic

Yixian Li1, Zongyu Li1, Hongxia Lu2

  • 1Department of Urology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.

European Urology Open Science
|January 19, 2026
PubMed
Summary

Olaparib combined with abiraterone significantly improves survival for BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC). For other homologous recombination repair-mutated mCRPC, olaparib monotherapy is effective.

Keywords:
AbirateroneBRCA mutatedHomologous recombination repairMetastatic castration-resistant prostate cancerOlaparib

More Related Videos

Murine Prostate Micro-dissection and Surgical Castration
08:49

Murine Prostate Micro-dissection and Surgical Castration

Published on: May 11, 2016

47.5K
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

7.2K

Related Experiment Videos

Last Updated: Jan 20, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.7K
Murine Prostate Micro-dissection and Surgical Castration
08:49

Murine Prostate Micro-dissection and Surgical Castration

Published on: May 11, 2016

47.5K
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

7.2K

Area of Science:

  • Oncology
  • Genetics
  • Pharmacology

Background:

  • Olaparib is an established treatment for metastatic castration-resistant prostate cancer (mCRPC).
  • Determining the optimal olaparib strategy based on genetic mutations is crucial for improving patient outcomes.
  • This study systematically reviews and analyzes existing clinical trial data.

Purpose of the Study:

  • To conduct a systematic review and network meta-analysis.
  • To identify the optimal olaparib treatment strategy for mCRPC.
  • To compare olaparib monotherapy versus combination therapies.

Main Methods:

  • Searched Cochrane, Embase, PubMed, and Web of Science databases for studies on mCRPC and olaparib.
  • Appraised study quality using NIH tools and analyzed data in R.
  • Primary endpoints: progression-free survival (PFS) and overall survival (OS); Secondary endpoints: adverse events.

Main Results:

  • Analyzed data from 9 studies involving 2355 patients.
  • For BRCA-mutated mCRPC, olaparib plus abiraterone significantly improved PFS (HR=0.61) and OS (HR=0.41) compared to olaparib alone.
  • No significant benefit of combination therapies over olaparib alone was found for other homologous recombination repair-mutated mCRPC.

Conclusions:

  • Olaparib combined with abiraterone demonstrates significant benefits for BRCA-mutated mCRPC.
  • Olaparib monotherapy is an effective treatment for BRCA wild-type homologous recombination repair-mutated mCRPC.
  • Treatment decisions for mCRPC should consider specific genetic mutations, particularly BRCA status.